Allergic reaction may occur against FIX protein in patients with hemophilia B
who have developed antibody in contrast to hemophilia A (5).
A review of the Hemophilia B
products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
33% cases of hemophilia A & hemophilia B
by us, compared to 100% in severe groups & 17.
Even such a tiny increase in factor IX could save the lives of people with hemophilia B
, who can suffer dangerous spontaneous bleeding in the joints or the brain, High says.
If they succeed with such animal experiments, researchers could begin human trials of gene therapy for hemophilia B
Prophylactic treatment for hemophilia A typically requires injections three times per week or every other day, and injections 2-3 times per week for the treatment of hemophilia B
, according to the National Hemophilia Foundation's Medical and Scientific Advisory Council guidelines.
A large number of respondents with mild/moderate hemophilia B
completed the survey, including affected women and parents of affected girls.
, also known as Christmas disease, is a less common type of hemophilia.
With only one recombinant protein currently available to treat hemophilia B
, it was important to focus research efforts on finding another option for patients with this debilitating disease," said lead investigator Jerzy Windyga, MD, PhD, Institute of Hematology and Blood Transfusion, Warsaw, Poland.
The investigational compound BAY 86-6150, is a novel recombinant factor VIIa (rFVIIa) protein for potential use in patients with hemophilia A or hemophilia B
who have developed neutralizing antibodies called inhibitors.
Global Markets Direct's, 'Hemophilia B
- Pipeline Review, H2 2012', provides an overview of the Hemophilia B
Inspiration's lead assets are IB1001, a recombinant factor IX in development for the treatment of hemophilia B
, and OBI-1, a recombinant porcine factor VIII in development for congenital hemophilia A with inhibitors and acquired hemophilia A.
Food and Drug Administration (FDA) for approval of BAX 326, a recombinant factor IX (rFIX) protein being investigated for the treatment and prophylaxis of bleeding episodes for patients over 12 years of age with hemophilia B
The recent developments in the respective field include gene therapy for treating hemophilia B
, half life extension of the recombinant coagulation factors, development of 4-factor PCC for reversal of vitamin K antagonist anticoagulant therapy along with recent approval of ADVATE in China apart from other clinical trials on run.
AskBio), for the development and commercialization of potential treatments for hemophilia B
utilizing Chatham's gene therapy technology.